DDInter1191 DDInter1676
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Methylprednisolone {u} (Compound) resembles {v} (Compound) Halobetasol Propionate
Methylprednisolone {u} (Compound) resembles {v} (Compound) Testolactone
Methylprednisolone {u} (Compound) treats {v} (Disease) rheumatoid arthritis
Methylprednisolone {u} (Compound) binds {v} (Gene) CYP3A4
Methylprednisolone {u} (Compound) upregulates {v} (Gene) ZFP36
Methylprednisolone {u} (Compound) palliates {v} (Disease) hematologic cancer
Methylprednisolone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Methylprednisolone {u} (Compound) downregulates {v} (Gene) FOSL1
Methylprednisolone {u} (Compound) causes {v} (Side Effect) Diplegia
Methylprednisolone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Methylprednisolone (Compound) resembles Halobetasol Propionate (Compound)
Methylprednisolone (Compound) resembles Testolactone (Compound)
Methylprednisolone (Compound) treats rheumatoid arthritis (Disease)
Methylprednisolone (Compound) binds CYP3A4 (Gene)
Methylprednisolone (Compound) upregulates ZFP36 (Gene)
Methylprednisolone (Compound) palliates hematologic cancer (Disease)
Methylprednisolone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Methylprednisolone (Compound) downregulates FOSL1 (Gene)
Methylprednisolone (Compound) causes Diplegia (Side Effect)
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid